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Uncoupling of photoreceptor peripherin/rds fusogenic activity f0rom
Biosynthesis, Subunit Assembly, and Targeting. A Potential Mechanism for
Pathogenic Effects
Abstract
Inherited defects in the RDS gene cause a multiplicity of progressive retinal diseases in humans. The gene
product, peripherin/rds (P/rds), is a member of the tetraspanin protein family required for normal
vertebrate photoreceptor outer segment (OS) architecture. Although its molecular function remains
uncertain, P/rds has been suggested to catalyze membrane fusion events required for the OS renewal
process. This study investigates the importance of two charged residues within a predicted C-terminal
helical region for protein biosynthesis, localization, and interaction with model membranes. Targeted
mutagenesis was utilized to neutralize charges at Glu321 and Lys 324 individually and in combination to
generate three mutant variants. Studies were conducted on variants expressed as 1) full-length P/rds in
COS-1 cells, 2) glutathione S-transferase fusion proteins in Escherichia coli, and 3) membrane-associated
green fluorescent protein fusion proteins in transgenic Xenopus laevis. None of the mutations affected
biosynthesis of full-length P/rds in COS-1 cells as assessed by Western blotting, sedimentation velocity,
and immunofluorescence microscopy. Although all mutations reside within a recently identified
localization signal, none altered the ability of this region to direct OS targeting in transgenic X. laevis
retinas. In contrast, individual or simultaneous neutralization of the charged amino acids Glu 321 and
Lys324 abolished the ability of the C-terminal domain to promote model membrane fusion as assayed by
lipid mixing. These results demonstrate that, although overlapping, C-terminal determinants responsible
for OS targeting and fusogenicity are separable and that fusogenic activity has been uncoupled from
other protein properties. The observation that subunit assembly and OS targeting can both proceed
normally in the absence of fusogenic activity suggests that properly assembled and targeted yet
functionally altered proteins could potentially generate pathogenic effects within the vertebrate
photoreceptor.
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Inherited defects in the RDS gene cause a multiplicity
of progressive retinal diseases in humans. The gene
product, peripherin/rds (P/rds), is a member of the tetraspanin protein family required for normal vertebrate
photoreceptor outer segment (OS) architecture. Although its molecular function remains uncertain, P/rds
has been suggested to catalyze membrane fusion events
required for the OS renewal process. This study investigates the importance of two charged residues within a
predicted C-terminal helical region for protein biosynthesis, localization, and interaction with model membranes. Targeted mutagenesis was utilized to neutralize
charges at Glu321 and Lys324 individually and in combination to generate three mutant variants. Studies were
conducted on variants expressed as 1) full-length P/rds
in COS-1 cells, 2) glutathione S-transferase fusion proteins in Escherichia coli, and 3) membrane-associated
green fluorescent protein fusion proteins in transgenic
Xenopus laevis. None of the mutations affected biosynthesis of full-length P/rds in COS-1 cells as assessed by
Western blotting, sedimentation velocity, and immunofluorescence microscopy. Although all mutations reside
within a recently identified localization signal, none altered the ability of this region to direct OS targeting in
transgenic X. laevis retinas. In contrast, individual or
simultaneous neutralization of the charged amino acids
Glu321 and Lys324 abolished the ability of the C-terminal
domain to promote model membrane fusion as assayed
by lipid mixing. These results demonstrate that, although overlapping, C-terminal determinants responsible for OS targeting and fusogenicity are separable and
that fusogenic activity has been uncoupled from other
protein properties. The observation that subunit assembly and OS targeting can both proceed normally in the
absence of fusogenic activity suggests that properly assembled and targeted yet functionally altered proteins
could potentially generate pathogenic effects within the
vertebrate photoreceptor.
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Rod and cone vertebrate photoreceptor outer segments
(OSs)1 contain hundreds of neatly stacked photopigment-containing membranous disks that are essential for normal vision.
A polarized renewal process replaces these membranes such
that a complete turnover of OS disks in rod cells is effected
approximately once every 10 days (1). Renewal is thought necessary to counter the effects of light damage and oxidation of
OS lipids, and evidence from several laboratories has shown
that a coordination of new disk assembly (morphogenesis) with
aged disk removal (shedding) is needed to maintain normal OS
structure (2, 3). Defects in disk morphogenesis or shedding that
compromise the renewal process lead to disorganization of the
OS layer and eventual photoreceptor cell death. Although OS
renewal has been linked to environmental factors including
light, temperature, and ionic milieu, the process is not currently well understood in molecular terms, particularly with
regard to regulation of the membrane fusion processes
required (2).
The rds (retinal degeneration slow) gene product, peripherin/
rds (P/rds; also known as photoreceptor peripherin, peripherin/
rds, rds/peripherin, rds, and peripherin-2), appears to be a
central player in OS morphogenesis and the renewal process.
First described in 1978, the rds mouse possesses a large insertion of viral DNA in chromosome 17 that results in a null allele
(4 – 6). Heterozygous and homozygous animals display irregular and absent OSs, respectively, with otherwise normal retinal
morphology at young ages (7, 8). Photoreceptor cell bodies
subsequently die by apoptosis, and deterioration of the photoreceptor cell layer in homozygotes is essentially complete by 12
months of age (9, 10).
Although clearly required for OS formation, the P/rds mechanism of action at the molecular level is less obvious. Studies
from several laboratories concur that it is an integral membrane protein localized to the rim regions of photoreceptor
disks in normal retina (11, 12). Present in all vertebrate rod
and cone photoreceptors examined to date, this protein causes
a variety of progressive retinal diseases in humans when defective (13). Proposals for function include disk rim formation,
disk flattening, disk stack scaffolding, disk-plasma membrane
interaction, and/or catalysis of disk renewal (14 –20). Compelling evidence to favor one clearly defined mode of action at the
1
The abbreviations used are: OS, outer segment; P/rds, peripherin/
rds; EC2, extracellular/intradiskal loop 2; CHR, C-terminal helical region; GST, glutathione S-transferase; GFP, green fluorescent protein;
WT, wild-type; mAb, monoclonal antibody; FRET, fluorescence resonance energy transfer; NBD-PE, N-(7-nitro-2,1,3-benzoxadiazol-4yl)phosphatidylethanolamine; Rh-PE, N-(lissamine rhodamine B sulfonyl)phosphatidylethanolamine; LUVs, large unilamellar liposomes;
diS-C3-(5), 3,3⬘-dipropylthiadicarbocyanine iodide; SUVs, small unilamellar vesicles.
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TABLE I
Synthetic oligonucleotides used for targeted mutagenesis
Variant

pGST-E321L
pGST-K324A
pGST-E321L,K324A

molecular level is still lacking. In some species, P/rds action can
be modulated by the presence of the homologous rom-1
polypeptide; however, the molecular function of rom-1 is also
unclear (21). A recent report describing the presence of a localization signal in the C terminus of P/rds (but not rom-1) suggests a rationale for why rom-1 knockout mice can elaborate
photoreceptor OSs, but P/rds null mice cannot (20).
We have previously used targeted mutagenesis to investigate P/rds structure-function relationships and to show that
folding and tetrameric subunit assembly are guided by discrete
determinants within the extracellular/intradiskal loop 2 (EC2)
domain (22). The vast majority of the predicted extramembranous polypeptide sequence, including a 66-amino acid C-terminal domain, makes no measurable contribution to protein biosynthesis. In contrast, several biophysical studies suggest that
the P/rds C terminus functions to catalyze membrane-membrane fusion events (17, 23–25). Those studies indicate that the
C terminus contains an amphipathic helix that functions as a
fusion peptide, and a recent investigation found that truncating the protein within the helix greatly diminishes fusogenic
activity (25).
Fusion peptides are short amphiphilic helical regions essential for the activity of known membrane fusion proteins (26,
27). Their amphiphilic character is thought to promote membrane destabilization via insertion into and disruption of bilayer structures; however, mechanisms of fusion peptide action
are still being widely debated and studied (27). Likewise, amphiphilicity appears to be important for the proposed P/rds
fusion peptide; the membrane destabilization activity of a P/rds
synthetic peptide model was strongly inhibited when its amphiphilicity was reduced by decreasing hydrophobicity (24). It
is noteworthy that rom-1, a peripherin/rds homolog, lacks
strong amphiphilicity in this region and is unable to promote
membrane fusion in vitro (28). In particular, rom-1 possesses
non-polar substitutions at two positions relative to the conserved P/rds fusion peptide sequence that result in a loss of two
charged residues (Glu321 and Lys324) and a decrease in predicted hydrophobic moment. The significance of charged residues in the P/rds fusion peptide has not been examined to date,
although ionizable amino acids are reported to play an important role in several other fusion peptides (27, 29).
An improved understanding of P/rds C-terminal structurefunction relationships is required to relate fusogenic activity
measured in vitro to its proposed molecular function in the
photoreceptor OS. This is an inherently difficult undertaking,
as there are no facile approaches to assay the membrane fusion
events involved in the vertebrate photoreceptor renewal process. This task is complicated by the recent identification of a
C-terminal OS localization signal that overlaps the previously
identified fusion peptide (20). This study examines the significance of two conserved charged residues, Glu321 and Lys324, to
further our understanding of how the C-terminal domain contributes to P/rds function. We find that these residues are
essential for P/rds fusogenic activity, but not biosynthesis, subunit assembly, or OS localization. The uncoupling of fusogenic
activity from other properties suggests that properly assembled

Oligonucleotides

5⬘-CCTTTCTGCTGAGTGTGAAGAAGCTGGGCA-3⬘ (forward)
5⬘-TGCCCAGCTTCTTCACACTCAGCAGAAAGG-3⬘ (reverse)
5⬘-GGCCTTTCTGGAGAGTGTGGCGAAGCTGG-3⬘ (forward)
5⬘-CCAGCTTCGCCACACTCTCCAGAAAGGCC-3⬘ (reverse)
5⬘-CTGAGTGTGGCGAAGCTGGGCAAGGGCAAC-3⬘ (forward)
5⬘-GTTGCCCTTGCCCAGCTTCGCCACACTCAG-3⬘ (reverse)

and targeted yet functionally altered proteins could generate
pathogenic effects in the vertebrate photoreceptor.
EXPERIMENTAL PROCEDURES

Engineering C-terminal Helical Region (CHR) Mutants for Expression in COS-1 Cells, Escherichia coli, and Xenopus laevis—Three sets of
constructs were used in this study (see Fig. 1C). The first set encodes
full-length (346 predicted amino acids) bovine P/rds for expression in
COS-1 cells and was used for the assay of protein biosynthesis and
subunit assembly. The second set of constructs, encoding only the
66-amino acid P/rds C-terminal domain fused to glutathione S-transferase (GST), was used to express and purify proteins from E. coli and
was used for assay of membrane interactions. Lack of cell-surface
expression in COS-1 cells precluded the routine use of full-length mutants for membrane interaction studies. The third set of constructs,
encoding the 66-amino acid P/rds C-terminal domain fused to green
fluorescent protein (GFP), was utilized to drive protein expression in
transgenic X. laevis for the assay of subcellular localization. Each set of
constructs includes wild-type (WT) P/rds and three variants, two single
missense mutations (E321L and K324A) and the combined double missense mutation (E321L,K324A).
The bacterial expression plasmids were based upon pGST-CTER, an
inducible expression vector encoding GST followed by the 66-amino acid
hydrophilic C terminus of WT bovine P/rds (25). Nucleotide base
changes were designed to introduce point mutations into the previously
identified fusion peptide region Val312–Leu326 (17, 24). In each instance,
a charged residue conserved across P/rds orthologs was replaced by an
uncharged residue from the homologous region of the aligned bovine
rom-1 sequence (see Fig. 1B). Single and double mutants were constructed serially using synthetic oligonucleotide primers (Table I) and
the QuikChange site-directed mutagenesis kit (Stratagene). Mutagenized regions were verified by DNA sequencing using a BigDye
terminator cycle sequencing kit (Applied Biosystems, Inc.). Mutagenized regions (as BamHI fragments) were returned to non-mutagenized expression vector backgrounds by subcloning to generate
bacterial expression plasmids pGST-E321L, pGST-K324A, and pGSTE321L,K324A. Correct assembly of the plasmids was confirmed by
restriction mapping.
The mammalian expression plasmids were based upon the bacterial
expression series described above and a cDNA clone encoding the fulllength WT P/rds sequence (30, 31). A 157-bp StuI/BamHI fragment
containing the mutagenized CHR was excised from each variant and
subcloned into the StuI/BamHI-digested subcloning vector pScXho (32).
The mutagenized CHRs were then excised as SacII/XhoI fragments and
ligated into SacII/XhoI-digested pcPERS, the non-mutagenized expression vector background containing the full-length protein coding region
of bovine P/rds (22). Completed constructs were confirmed by
restriction mapping.
The constructs designed for expression of mutant variants in transgenic X. laevis were based on the plasmid pEGFP-C1 (Clontech). The
cytomegalovirus promoter was replaced with a 0.8-kb fragment of the
proximal X. laevis opsin promoter (pXOP-0.8). Following the GFP
cDNA, a sequence encoding the C terminus of X. laevis rhodopsin
lacking the terminal five amino acids (i.e. amino acids 311–348) was
inserted to create pXOP-0.8-EGFP-rhoCT. This plasmid was designed
to accept the BamHI fragments encoding the 66 amino acids of bovine
P/rds (described above) in-frame behind the GFP-rhodopsin sequence.
The presence of a palmitoylation signal within the rhodopsin sequence
creates a membrane-bound GFP reporter molecule (20). The desired
constructs were selected and verified by restriction mapping. The previously described constructs GFP-rhoCT44 and GFP-rhoCT44del5 were
also used as controls (33).
Assay of Expression and Disulfide Bonding in COS-1 Cells—P/rdscontaining membranes were prepared at 4 °C from transiently transfected COS-1 cells as follows. Adherent cells grown on 100-mm plastic
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culture dishes were washed three times with Tris-buffered saline 48 h
post-transfection. Cells were scraped from plates with a rubber policeman and collected into 1 ml of Tris-buffered saline containing 2.5 mM
N-ethylmaleimide, 1 g/ml leupeptin, 1 g/ml pepstatin A, and 5 g/ml
Pefabloc-SC (Roche Applied Science). The cells were pelleted by centrifugation at 2000 ⫻ g for 10 min at 4 °C. The cell pellets were resuspended in 1.2 ml of 10 mM Tris-HCl (pH 7.5) containing 2.5 mM Nethylmaleimide, 1 g/ml leupeptin, 1 g/ml pepstatin A, and 5 g/ml
Pefabloc-SC. The resuspended cells were passed forcefully through
26-gauge syringe needles five times, and the resulting lysates were
centrifuged at 1000 ⫻ g for 10 min at room temperature. Supernatants
were transferred to ultracentrifuge tubes and centrifuged at 110,000 ⫻
g for 20 min at 4 °C. The membrane pellets were resuspended by
vortexing and trituration in 115-l aliquots of Tris-buffered saline
containing 2.5 mM N-ethylmaleimide, 1 g/ml leupeptin, 1 g/ml pepstatin A, and 5 g/ml Pefabloc-SC. COS-1 cell membranes prepared in
this fashion were stored at ⫺70 °C until used.
Western blot analysis of WT and mutant P/rds expression and disulfide bonding in transfected COS-1 membranes was performed using
anti-P/rds monoclonal antibody (mAb) C6 and methods described previously (22). Thawed COS-1 cell membranes (3 l/lane) were solubilized
with denaturing sample buffer containing 5% ␤-mercaptoethanol, and
samples were heated in boiling water for 5 min prior to loading onto
10% SDS-polyacrylamide gels. Analysis of disulfide bonding was performed in an analogous manner in the absence of ␤-mercaptoethanol.
Immunofluorescent Localization in COS-1 Cells—WT and mutant
P/rds were localized in transiently transfected COS-1 cells as described
previously (22). In brief, paraformaldehyde-fixed cells were permeabilized with Triton X-100 and then processed using anti-P/rds mAb C6
and a secondary anti-mouse IgG antibody covalently labeled with the
Cy3 fluorophore (Amersham Biosciences). A similar procedure used a
1:200 dilution of a mouse anti-KDEL receptor monoclonal antibody
(Stressgen Biotech Corp.) in conjunction with a secondary anti-mouse
IgG antibody covalently labeled with the Cy2 fluorophore (Amersham
Biosciences) to label cis-Golgi and intermediate Golgi membranes. Likewise, a 1:200 dilution of a rabbit anti-calnexin polyclonal antibody
(Stressgen Biotech Corp.) was used in conjunction with a secondary
anti-rabbit IgG antibody covalently labeled with the Cy2 fluorophore to
label the endoplasmic reticulum. A Nikon Optiphot-2 microscope
equipped with an epifluorescent illuminator and a SPOT RT digital
imaging system (Version 3.0 software, Diagnostic Instruments Inc.)
were utilized for image acquisition. Image processing was limited to
adjustment of brightness and contrast.
Assay of Subunit Assembly by Velocity Sedimentation—A previously
established procedure was used to measure the sedimentation velocities
of detergent-solubilized WT and mutant P/rds; a Beckman Optima TLX
centrifuge and TLS-55 rotor were utilized as described previously (34).
In brief, Triton X-100 extracts of transiently transfected COS-1 cells
were layered onto 2-ml 5–20% sucrose gradients and centrifuged overnight at 4 °C. Soluble fractions were collected by off-center puncture of
tube bottoms; particulate fractions were collected by solubilization of
pellets with Laemmli sample buffer. Scion Image software was utilized
for image analysis of chemiluminescent Western blots; pixel summation
over soluble and particulate fractions was used to calculate total P/rds
reactivity (22). Peak immunoreactivities were taken for the calculation
of s20,w values.
Mutant Expression and Subcellular Localization in Transgenic
X. laevis Retina—Transgenic tadpoles were generated using a modified
protocol (36) based on that of Kroll and Amaya (35). WT X. laevis adults
were obtained from Xenopus I (Dexter, MI). X. laevis sperm nuclei were
incubated with 0.3⫻ high speed egg extract, 0.05 units of NotI restriction enzyme, and 100 –200 ng of NotI-linearized vector DNA in a total
volume of 18 l. After 10 min, the reaction mixture was diluted to 0.3
nuclei/nl, and 10 nl was injected per egg. The resulting embryos were
reared in 0.1⫻ Marc’s modified Ringer’s solution containing 6% Ficoll
and 50 g/ml gentamycin for 48 h and then transferred to 0.1⫻ Gerhart’s modified Ringer’s solution (37). Animals were treated with 18
g/ml G418 for 96 h as previously described to select for transgenic
animals and to reduce the extent of gene silencing (38). At 5– 6 days
post-fertilization, roughly corresponding to stages 40 – 42, tadpoles were
screened for GFP expression using a Zeiss Axioskop equipped with
epifluorescence optics and a GFP filter set (39). Tadpoles expressing
GFP were identified by green fluorescence emitted from their eyes. All
animals were raised at 18 °C on a 12/12 light cycle (8 a.m. to 8 p.m.).
Stage 48 – 62 transgenic tadpoles were killed between 4 and 7 p.m.
(i.e. near the end of the light cycle) and fixed in 4% paraformaldehyde
and 0.1 M sodium phosphate (pH 7.4). Fixed eyes were embedded in
OCT tissue embedding medium (Tissue-Tek) and cryosectioned. Frozen

sections (14 m) were stained with Texas Red-conjugated wheat germ
agglutinin (Molecular Probes, Inc., Eugene, OR) and Hoechst 33342
(Sigma) to label Golgi/post-Golgi membranes and nuclei, respectively,
as previously described (20). Labeled sections were mounted in 50%
glycerol. A Zeiss LSM 510 laser scanning confocal microscope equipped
with a C-Apochromat (40⫻ W Korr, 1.2-numerical aperture objective)
and Zeiss LSM software were used to acquire images of labeled sections.
At least three transgenic animals were examined by confocal microscopy for each construct.
Expression and Purification of GST-C-terminal Domain Fusion Proteins—A standardized expression and purification procedure based on
methods developed for pGST-CTER was used. Thirty ml of a plasmidtransformed, freshly saturated E. coli XL1-Blue culture was used to
inoculate 900 ml of Luria broth containing 100 g/ml ampicillin. The
culture was grown with agitation at 37 °C for 1.5 h, and fusion protein
expression was induced for an additional 3 h (with agitation at 37 °C) by
the introduction of 0.1 mM isopropyl-1-thio-␤-D-galactopyranoside. Cells
were collected by centrifugation and stored at ⫺70 °C until used.
The frozen cell pellet was thawed on ice and resuspended by vortexing in 35 ml of ice-cold phosphate-buffered saline (pH 7.5) containing 1
mM dithiothreitol, 1 g/ml leupeptin, 1 g/ml pepstatin A, and 1 mM
phenylmethylsulfonyl fluoride. The cells were lysed using a French
pressure cell, and Triton X-100 was added to a final concentration of
1%. The lysate was stirred for 20 min at 4 °C and then centrifuged at
14,000 ⫻ g for 30 min at 4 °C. The clarified supernatant was applied to
a 6-ml column of packed glutathione-Sepharose 4B (Amersham Biosciences), and the column was washed with 10 bed volumes of phosphate-buffered saline. The GST-C-terminal domain fusion protein was
eluted by three sequential single bed volume equilibrations of 5 min
each using 50 mM Tris-HCl (pH 8.8) containing 10 mM reduced glutathione and 1 mM dithiothreitol. Combined eluates were concentrated
with a stirred ultrafiltration cell; dialyzed at 4 °C against 50 mM TrisHCl (pH 7.0), 150 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol; and
stored in aliquots at ⫺80 °C. Protein determinations were carried out
with a BCA assay kit (Pierce) using bovine serum albumin to construct
the standard curve.
Assay of Vesicle Fusion by Lipid Mixing—An established procedure
was adapted to measure lipid mixing using fluorescence resonance
energy transfer (FRET) (40). This assay is based on the dilution of a
resonance energy transfer pair, N-(7-nitro-2,1,3-benzoxadiazol-4yl)phosphatidylethanolamine (NBD-PE) and N-(lissamine rhodamine B
sulfonyl)phosphatidylethanolamine (Rh-PE) (Molecular Probes, Inc.),
due to vesicle hemifusion and subsequent NBD-PE dequenching. Large
unilamellar vesicles (LUVs) were prepared from phosphatidylcholine/
phosphatidylserine/cholesterol (4:4:1; Avanti Polar Lipids Inc.,
Birmingham, AL) by extrusion through a 0.1-m filter essentially as
described by Mayer et al. (41). LUVs containing 0.6 mol % Rh-PE and
0.6 mol % NBD-PE were mixed at a 1:1 molar ratio with an unlabeled
(but otherwise identical) population of LUVs (10 M phospholipid final
concentration) and a purified mutant variant (8.3 g/ml final protein
concentration). The rhodamine excitation wavelength was set at 465
nm; NBD fluorescence emission was measured at 530 nm; and a 515-nm
cutoff filter was used between the sample and the emission monochromator to decrease interference from light scattering. Under these conditions, vesicle hemifusion results in probe dilution and a linear increase in NBD-PE fluorescence (40). FRET was measured after 10 min
(its maximal value); percent FRET was calculated as described previously (25). No above base-line changes were observed for additions of
purified GST alone (8.3 g of protein/mg of total lipid).
Assay of Membrane Destabilization by Vesicle Depolarization—Membrane bilayer destabilization was inferred from membrane depolarization studies and measured fluorometrically with the cation-sensitive
dye 3,3⬘-dipropylthiadicarbocyanine iodide (diS-C3-(5); Molecular
Probes, Inc.) as a collapse in a valinomycin-induced diffusion potential.
Small unilamellar vesicles (SUVs) were prepared by sonication from
phosphatidylcholine/phosphatidylserine/cholesterol at a 4:4:1 molar ratio in the presence of 100 mM K⫹ and then diluted into K⫹-free isotonic
buffer (3.6 M phospholipid final concentration). The fluorescent probe
diS-C3-(5) was added to 1 nM and allowed to equilibrate at 37 °C until a
stable base-line fluorescence (ex ⫽ 620 nm and em ⫽ 670 nm) was
established. The K⫹ ionophore valinomycin was added to 0.1 mM to
create an inside negative electrochemical potential that resulted in
diS-C3-(5) quenching. Purified GST fusion proteins (10 g/ml protein
final concentration) were assayed individually for their ability to induce
SUV leakiness and to dissipate the diffusion potential as measured by
diS-C3-(5) fluorescence recovery. A similar concentration of purified
GST had no effect on fluorescence recovery. Percent fluorescence recoveries were calculated as described (42).

Uncoupling of Photoreceptor Peripherin/rds Fusogenicity

39961

RESULTS

Design and Construction of CHR Mutants—We have shown
previously that defects in P/rds can cause discrete and local as
well as global disruptions of protein structure (22, 32, 43). Most
recently, an insertion mutagenesis approach demonstrated
that, although the vast majority of extramembranous polypeptide sequence makes no measurable contribution to gross protein folding or tetramerization, discrete regions within the EC2
domain do include determinants required for normal subunit
assembly (22). That study aimed to identify regions making
specific local contributions; therefore, mutations were inserted
outside the boundaries of strongly predicted secondary structures, including an ␣-helix in the C terminus that promotes
model membrane fusion (17).2 In this study, we examined
whether targeted point mutations within the CHR affect
known structural and/or functional properties of P/rds.
Seventeen highly conserved C-terminal amino acids (Val312–
Lys328), including a minimal region (Val312–Leu326) previously
shown to adopt a helical structure and to promote model membrane fusion (17, 24), are shown in Fig. 1B. The alternation of
charged (boxed) and relatively hydrophobic residues with a
three- to four-residue periodicity predicts a highly amphipathic
structure, characteristic of a membrane-binding helix. In contrast, rom-1 lacks both this motif and fusogenic activity (28).
Since two charged residues (Glu321 and Lys324) are missing
from rom-1, we wondered whether these charges are important
for P/rds fusogenic activity. We also asked whether these
charges are necessary for OS localization of P/rds, given the
presence of a subcellular localization signal within this same
region (20).
To test these hypotheses, we constructed a set of potentially
non-fusogenic P/rds variants by targeted mutagenesis of the
CHR (Fig. 1B). Charged amino acid residues at two positions
(Glu321 and Lys324) were substituted individually and in combination with the corresponding uncharged residues found in
the aligned bovine rom-1 sequence. None of the mutant variants are predicted (using the NNPREDICT algorithm) to possess significantly altered ␣-helical character (44). Mutants
were expressed as full-length (polytopic) proteins in COS-1
cells, as GST-C-terminal domain fusions in E. coli, and as
C-terminal domain fusions with membrane-associated GFP in
transgenic X. laevis photoreceptors (Fig. 1C).
Heterologous Expression and Disulfide Bonding of CHR Mutants in COS-1 Cells—Each of the full-length variants was
individually transfected into COS-1 cells in culture, and protein expression was assessed by Western blot analysis using
anti-P/rds mAb C6. This reagent recognizes an epitope at the
distal C terminus and is therefore a good diagnostic measure of
full-length protein expression (22). The mutagenized CHR lies
⬃21 amino acids upstream of this epitope, and mutations do
not appear to affect antibody binding. All mutants expressed
robustly; the Western blot analysis shown in Fig. 2 (left panel)
demonstrates that, under denaturing and reducing conditions,
all mutants possessed apparent molecular masses comparable
with that of WT P/rds.
Mutant protein mobility was also characterized by Western
analysis in the absence of added reducing agent. It is well
established that WT P/rds adopts a disulfide-bonded dimeric
form both in vertebrate retina and in COS-1 cells (15, 30, 31).
Several examples of human retinal disease likely involve protein misfolding as a consequence of abnormal disulfide bonding
(45– 48). All three C-terminal domain mutants displayed essen-

2
Fusion is defined operationally as lipid mixing in this study. No
distinction is drawn or intended between hemifusion and bona fide
fusion.

FIG. 1. A, domain organization of P/rds. Four transmembrane domains (TM1– 4) and the presence of several cysteine-containing motifs
(not shown) in EC2 indicate a relationship within the tetraspanin
family of proteins. CTER, C-terminal domain. B, alignment of the P/rds
and rom-1 sequences for the predicted CHR at positions 312–328 within
the 66-amino acid C-terminal domain. Conserved charged residues with
three- to four-residue spacing are evident for P/rds. This study investigated the importance of the conserved charges at positions 321 and 324
for protein structure, localization, and fusogenic activity. Substitutions
were guided by the aligned rom-1 sequences. The 15-amino acid bovine
(Bov) P/rds region previously implicated as a fusion peptide is shaded.
A recently reported localization signal (20) includes an additional five
amino acids upstream and eight amino acids downstream of the X.
laevis (Xen) sequence depicted. Mus, Mus musculus; Hum, human. C,
mutant P/rds variants expressed as 1) full-length polytopic proteins in
COS-1 cells for assay of protein biosynthesis, 2) C-terminal domain
fusions with GST in E. coli, and 3) C-terminal domain fusions with GFP
modified with a rhodopsin palmitoylation signal. This latter molecule
acts as membrane-bound localization reporter in X. laevis (33).

tially WT behavior (Fig. 2, right panel); all migrated as both
monomeric and (disulfide-bonded) dimeric forms. In sum, the
data presented demonstrate that none of the C-terminal domain mutations measurably affect normal expression or disulfide bonding of P/rds in COS-1 cells.
Immunofluorescent Localization of CHR Mutants in COS-1
Cells—Immunofluorescence microscopy was used to examine
whether neutralization of charged residues in the CHR affects
subcellular localization of full-length P/rds variants expressed
in transiently transfected cultured cells. Properly assembled
WT P/rds displays a largely perinuclear distribution in COS-1
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FIG. 2. Assay of CHR mutant expression and disulfide bonding
in COS-1 cells by Western blot analysis. COS-1 cells were transfected with plasmids encoding full-length mutant P/rds variants: single
mutants E321L and K324A and double mutant E321L,K324A. Transfected COS-1 cell membranes were treated with N-ethylmaleimide to
block free thiols and then solubilized in denaturing SDS gel loading
buffer. Samples were subjected to reducing (with ␤-mercaptoethanol (⫹
␤-ME)) or nonreducing (⫺ ␤-ME) SDS-PAGE (10% resolving gels) and
then electroblotted onto Immobilon-P membrane and probed with antiP/rds mAb C6. All CHR mutants expressed robustly; moreover, each
showed the ability to form disulfide-linked dimers, akin to WT P/rds.

cells, suggesting that it remains associated with Golgi membranes; in contrast, grossly misfolded P/rds is retained within
the endoplasmic reticulum (22). A recent demonstration that a
targeting signal is encoded within the P/rds C terminus (20)
prompted us to examine whether mutations in the CHR affect
targeting in transfected COS-1 cells.
Indirect immunofluorescence was used to analyze the subcellular distribution of CHR mutants in fixed and permeabilized COS-1 cells. All CHR mutants appeared to be essentially
indistinguishable from WT P/rds; we were unable to discern
any effects of the mutations on protein distributions. Fluorescence distributions were somewhat heterogeneous between individual cells; images presented are representative of the most
common localization patterns. Reference images of endoplasmic reticulum and Golgi immunofluorescence labeling patterns
are shown for comparison, as is the distribution of grossly
misfolded P/rds (Fig. 3A). The subcellular distribution of WT
P/rds is also shown in Fig. 3B; the protein displayed a largely
Golgi distribution, appearing as a small cap over nuclei of
transfected cells. These results demonstrate that subcellular
localization patterns of P/rds are not significantly altered by
mutations that neutralize conserved CHR residues.
Subunit Assembly of CHR Mutants Expressed in COS-1
Cells—Point mutations that prevent the normal formation of
tetrameric P/rds cause progressive retinal disease in humans
and dysmorphic OSs in transgenic mice (34, 43, 49). We recently established a primary role for EC2 in this process and
showed that discrete determinants within the EC2 domain
guide tetramer formation (22). Although no ill effects of Cterminal domain insertion mutations on subunit assembly
were found, none of the insertions disrupted the CHR directly.
Therefore, we have examined whether the neutralization of
charged residues in the CHR can affect tetrameric assembly
of P/rds.
Subunit stoichiometry was assessed using a velocity sedimentation technique developed previously (31). Full-length WT
and mutant P/rds were expressed by transient transfection of
COS-1 in culture; the cells were extracted with Triton X-100
under nondenaturing conditions; lysates were applied to sucrose gradients; and the gradients were centrifuged overnight.
Fractionated gradients were assayed by Western blot analysis
to determine protein mobility and to calculate sedimentation
coefficients. Comparison of the mobility of a given mutant
relative to that of WT P/rds was used to assess tetrameric

FIG. 3. Subcellular localization of CHR mutants by indirect
immunofluorescence microscopy. A, characteristic endoplasmic reticulum (anti-calnexin antibody), Golgi (anti-KDEL receptor antibody),
and misfolded P/rds (anti-P/rds mAb C6, green) localization patterns
are presented for reference. Misfolding of P/rds variant IM7b has been
reported previously (22). B, COS-1 cells transiently transfected with
WT P/rds or the indicated mutant expression vectors were fixed with
paraformaldehyde, permeabilized with Triton X-100, and labeled with
anti-P/rds mAb C6 (red) and 4⬘,6-diamidino-2-phenylindole nuclear
stain (blue). All CHR mutants displayed mainly perinuclear distributions characteristic of localization within the Golgi apparatus, akin to
WT P/rds.

assembly. Fig. 4 illustrates typical sedimentation profiles obtained for WT and mutant P/rds. In each case, greater than half
of the P/rds reactivity remained in the soluble (versus particulate) fraction. Thus, these mutations do not cause extensive
protein misfolding. In addition, the mobility of each variant is
most consistent with tetrameric stoichiometry; sedimentation
coefficients, calculated from immunoreactivity peaks, are presented in Table II. The results demonstrate that none of the
CHR mutations significantly affected gross folding or subunit
assembly of full-length P/rds in COS-1 cells.
Targeting and Localization in Transgenic X. laevis Rod Photoreceptors—We utilized a recently developed confocal fluorescence assay to investigate whether the mutations we introduced into the CHR affect the ability of the C terminus of
bovine P/rds to direct photoreceptor OS targeting and localization (20). This approach uses an X. laevis opsin promoter to
drive expression of a membrane-associated GFP reporter fused
to C-terminal domain variants of bovine P/rds in transgenic X.
laevis rod photoreceptors (33, 38). When the WT bovine P/rds C
terminus is fused to the GFP reporter, nearly all fluorescence
retargets to the OS, the normal location of full-length endogenous P/rds. Importantly, the fluorescent reporter does not form
complexes with full-length P/rds (20). The combined results
indicate the presence of a localization signal in the P/rds C
terminus that does not require other protein domains for targeting. Analysis of mutant targeting requires the use of a P/rds
fragment since transgenic expression of full-length P/rds mutants would most likely result in co-assembly with the high
background of endogenous P/rds and masking of potential targeting defects (22, 31, 38, 50).
Fig. 5 (A–C) shows typical localization patterns observed for
the WT bovine sequence and the single mutant E321L and the
double mutant E321L,K324A. As described previously (20) and
as shown in Fig. 5A, the WT bovine P/rds C terminus directed
the vast majority of membrane-associated GFP to the rod photoreceptor OS; only very minor amounts of GFP fluorescence
are detectable in other regions (20). This distribution is similar
to that generated by the WT X. laevis rhodopsin C terminus
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TABLE II
Consequences of CHR mutations on subunit assembly and
sedimentation coefficients
Velocity sedimentation coefficients (s20,w) for full-length mutant variants are given as means ⫾ S.D. The number of independent transfection/sedimentation trials for each is given in parentheses. WT P/rds
from detergent extracts of transfected COS-1 cells sediments as a characteristic tetramer under reducing conditions in 5–20% (w/w) sucrose
gradients (31). None of the mutations assayed measurably affected
P/rds subunit assembly.

FIG. 4. Subunit assembly assay of full-length CHR mutants by
velocity sedimentation. Detergent extracts from transiently transfected COS-1 cell cultures were sedimented under reducing conditions
in 5–20% (w/w) sucrose gradients. Fractionated gradients (and particulate fractions (P)) were assayed for P/rds by Western blot analysis with
mAb C6. Representative chemiluminescent blots and corresponding
plots generated by image analysis are shown for WT P/rds, a previously
characterized dimeric insertion mutant (IM10), and the three mutant
CHR variants. Immunoreactivity in sucrose gradient fractions was
calculated as a percentage of the total (soluble and particulate immunoreactivity); in all cases, the majority of the P/rds reactivity remained
in the soluble (versus particulate) fraction. As reported previously (22),
WT P/rds sediments as a single major peak characteristic of a tetrameric stoichiometry, but IM10 displays a subunit assembly defect. All
of the CHR mutants sedimented like the WT protein, indicating that
each is tetrameric and that subunit assembly is unaffected by charge
neutralizations in the CHR. Sedimentation coefficient estimates for all
variants were calculated as described under “Experimental Procedures”
and are reported in Table II.

(Fig. 5D), the first OS localization signal identified (33). The
subcellular distributions of the mutant P/rds variants were
essentially indistinguishable from that of WT P/rds; no effect of
these mutations on the ability of the C-terminal domain to
direct OS localization was observed (Fig. 5, A–C). In contrast
and for the sake of comparison, Fig. 5E shows the appearance
of membrane-associated GFP lacking an OS localization signal.
As reported previously (33), disruption of the X. laevis rhodopsin localization signal (by truncation) results in broader distributions that include both lateral plasma membranes and internal membranes of the inner segment and a clear presence in

P/rds

s20,w

WT
E321L
K324A
E321L,K324A

5.4 ⫾ 0.2 (8)
5.3 ⫾ 0.5 (4)
5.5 ⫾ 0.2 (3)
5.4 ⫾ 0.1 (3)

Stoichiometry

Tetrameric
Tetrameric
Tetrameric
Tetrameric

outer plexiform layer membranes. The K324A single mutant
was not assayed directly; but given the lack of effect seen for
the double mutant (Fig. 5C), it is likely that K324A would also
have no disruptive effect.
In Vitro Fusogenicity of CHR Mutants Expressed as GST
Fusion Proteins in E. coli—We adapted a FRET approach to
investigate whether charged residues in the CHR are important for P/rds fusogenic activity in vitro. Previous studies have
shown that the P/rds C terminus, and more specifically, the
CHR, can promote membrane vesicle fusion and that controlled
trypsinolysis (or genetic truncation) results in loss of fusogenic
activity (17, 24). Importantly, the homologous bovine rom-1
polypeptide sequence lacks several charged residues in this
region (Fig. 1B) and does not show fusogenic activity in vitro
(25). We hypothesized that neutralizing these charged residues
with neutral residues present in rom-1 would inhibit P/rds
ability to promote model membrane fusion. Fusogenicity was
assayed using purified bacterially expressed proteins, as a lack
of cell-surface expression of P/rds in COS-1 adversely affected
signal-to-noise ratios in assays using COS-1 membranes.3
Each of the variants was expressed as a GST fusion protein
and subsequently purified by affinity chromatography. The
appearance of each relative to the GST-tagged WT P/rds C
terminus (GST-WT) and GST alone is shown in Fig. 6 by
Coomassie Blue staining. Each variant (including WT P/rds)
ran with an apparent molecular mass of ⬃28 kDa, near that of
the combined predicted masses of ⬃22 and ⬃6 kDa of GST and
the P/rds C terminus, respectively. Each preparation also contained several species of greater mobility, most likely truncation products. In each case, at least 70% of the total protein was
judged to be full-length.
LUVs containing Rh-PE and NBD-PE were mixed at a 1:1
molar ratio with unlabeled LUVs (100 nM phospholipid final
concentration). Fig. 7A shows how NBD-PE fluorescence intensity changed upon addition of the purified GST-C-terminal
domain proteins. Consistent with a previous report (25),
GST-WT promoted LUV fusion that resulted in lipid mixing,
subsequent probe dequenching, and fluorescence increase. This
approach was used to compare the fusogenic activity of the
purified CHR mutants with that of WT P/rds. We found that
fusogenic activity required both conserved charged residues in
the CHR. Nearly complete inhibition resulted when single
charges were neutralized at Glu321, Lys324, or both simultaneously. The net charge change (relative to the WT sequence)
for these three variants is ⫹1, ⫺1, and 0, respectively, yet they
impacted activity in an almost equivalent fashion. Thus, a
simple relationship between fusogenicity, as measured by lipid
mixing, and net charge change is not supported by these data.
Instead, we found that any alteration of charge at these two
3
K. Boesze-Battaglia, L. M. Ritter, and A. F. X. Goldberg, unpublished data.
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FIG. 5. Localization of GFP-P/rds C-terminal domain fusion protein variants expressed in transgenic X. laevis rod photoreceptors.
Confocal microscopy was performed on cryosections from stage 48 – 62 transgenic tadpole eyes expressing membrane-associated GFP fusions with
WT P/rds (A), E321L (B), and E321L,K324A (C). GFP fusion proteins (green) were found almost exclusively in the outer segments (OS), with
minimal localization observed elsewhere (arrowheads). Thus, neutralization of CHR charged residues at positions 321 and 324 does not disrupt the
normal localization of P/rds to the OS. Shown in D is a section from a control eye showing OS localization driven by GFP-rhoCT44, which contains
a rhodopsin OS localization signal (33). Shown in E is a section from a control eye showing an example of delocalization displayed by
GFP-rhoCT44del5, which lacks an OS localization signal (33). In addition to OS localization, abundant GFP fluorescence was observed in the
lateral plasma membranes and internal membranes of inner segments (IS) as well as outer plexiform layer (OPL) membranes (arrowheads). Shown
in F is a section from a control eye in which no GFP was expressed. Red indicates Texas Red-conjugated wheat germ agglutinin, and blue indicates
Hoechst 33342. Bar ⫽ 20 m.

FIG. 6. Expression and purification of GST-P/rds C-terminal
domain fusion proteins. The C-terminal domain for each variant was
expressed as a GST fusion protein in E. coli by induction with isopropyl1-thio-␤-D-galactopyranoside. Purification was performed using a glutathione-agarose affinity matrix, and eluted proteins (predicted masses
of ⬃28 kDa) are shown separated by 15% SDS-PAGE and stained with
Coomassie Blue. Each was routinely purified to ⬎70% purity; truncated
products, including GST, constitute the majority of the remaining
impurities.

positions largely abrogated the ability to promote model membrane fusion.
Membrane Destabilization of CHR Mutants Expressed as
GST Fusion Proteins in E. coli—Although the mechanism(s) by
which the CHR promotes model membrane fusion is not understood, current evidence suggests that it involves binding
and destabilization of phospholipid membranes (24, 25). Given
that each of the CHR mutants we examined inhibited fusogenic
activity, a vesicle depolarization assay was adopted to investigate whether any of these mutations acts by preventing membrane destabilization.
Purified GST-C-terminal domain fusion proteins were assayed for their ability to induce SUV leakiness as measured by
membrane potential collapse. Fig. 7B shows the fluorescence
intensity increase of the potentiometric dye diS-C3-(5) due to
SUV membrane destabilization upon addition of GST-WT. We
compared the destabilization activity of the purified CHR mutants relative to that of WT P/rds. As shown in Fig. 7B, we
found that destabilization, like fusogenic activity, was severely
inhibited by neutralization of single charges at both positions
321 and 324. Surprisingly and in contrast to fusogenic activity,

FIG. 7. Membrane interactions of P/rds CHR mutants. A, assay
of fusogenicity (lipid mixing) as measured by FRET. Affinity-purified
GST fusion proteins (8.3 g/ml final concentration) were added individually to LUVs containing the lipophilic fluorophores Rh-PE and
NBD-PE in the presence of additional unlabeled vesicles (10 M phospholipid final concentration). Neutralization of Glu321, Lys324, or both
significantly impaired the ability of the P/rds C terminus to mediate
vesicle fusion. Error bars represent S.D. B, membrane destabilization
by GST-P/rds C-terminal domain fusion proteins. The potentiometric
dye diS-C3-(5) was utilized to measure the ability of the CHR variants
to induce membrane leakiness in SUVs (42). Membrane destabilization
was inferred from the ability of the variants (10 g/ml protein final
concentration) to collapse the membrane potential and to allow diS-C3(5) fluorescence recovery (25). Neutralization of either Glu321 or Lys324
abrogated the ability of the P/rds C terminus to depolarize SUVs; in
contrast, simultaneous neutralization of Glu321 and Lys324 significantly
enhanced SUV depolarization.

destabilization activity was significantly enhanced when these
two charges were neutralized simultaneously (E321L,K324A).
Overall, these data indicate that, like in vitro fusogenic activ-
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ity, membrane destabilization is not simply related to charge
density and, furthermore, that multiple mechanisms underlie
the observed loss of fusogenicity.
DISCUSSION

Early structure-function studies of P/rds focused upon the
EC2 domain; this region includes the majority of the hydrophilic protein sequence (⬃150 amino acids) and is the site of
both the rds mouse defect and the originally described human
disease-related mutations (13, 16, 34, 49, 51–57). In contrast,
the smaller 66-amino acid C terminus has to date been the
subject of more limited attention (17, 20, 24, 25). Recent investigations, including this study, suggest that its importance may
previously have been overlooked. We used sequence analysis
and engineered missense mutations to investigate the role of
conserved charged residues in the amphiphilic CHR and found
these sites are essential for fusogenic activity, but not biosynthesis, subunit assembly, or OS localization. The fact that these
properties can be uncoupled suggests that inherited mutations
in the C terminus might impair OS structure and photoreceptor viability by specifically disabling membrane fusion.
Several lines of evidence had led us to speculate previously
that the C-terminal domain plays a greater role in P/rds function than in protein structure (3). First, a transgenic mouse
model demonstrates that one or more domains in addition to
EC2 are required for generating and maintaining OS architecture (54). Second, P/rds subunit assembly and export from the
endoplasmic reticulum are both dependent upon determinants
residing within the EC2 domain; insertion mutations in the C
terminus do not measurably affect these processes (22). Third,
reports of inherited genetic defects in humans and an engineered mutant mouse model both show that retinal physiology
can be adversely affected by an abnormal C terminus (13, 59).
Finally, several studies have documented the ability of the C
terminus to promote model membrane fusion (17, 24, 25, 60).
This study was based in part on the presence of an amphipathic helix in the P/rds C terminus; this feature was initially suggested by sequence analysis and later confirmed by a
Fourier transform IR study of a synthetic peptide (17, 24). This
region, Val312–Leu326 in the original investigation, has been
proposed to act as a fusion peptide, a sequence that, when
triggered, can insert into and promote fusion of apposed biological membranes. Fusion peptides required for membrane
fusion in viral entry are particularly well studied (26, 61).
Numerous mutagenesis studies have demonstrated that alteration of fusion peptide sequence can strongly and specifically
affect the fusogenic activity of the larger fusion protein and
indeed the entire organism (as in a virus) (62– 64). Similarly, a
previous study of P/rds fusogenicity suggests that its activity is
strongly impacted by changes in the fusion peptide sequence
(24). Most recently, a recombinant version of the P/rds C terminus was shown to induce model membrane destabilization
and fusion (25). Since the P/rds homolog rom-1 does not display
this activity, we wondered whether differences in the CHR
might contribute to the observed disparity in fusogenic activity
(28). Therefore, we replaced conserved charged residues in
P/rds with neutral residues from the aligned region of rom-1
(Fig. 1B). We reasoned that using a P/rds homolog to guide our
choice of neutralizing substitutions would provide the greatest
likelihood of maintaining normal protein structure. Secondary
structure predictions indicated that helical structure would be
preserved for each of the CHR mutants.
In fact, none of the CHR mutants produced measurable
effects on any aspect of protein biosynthesis in COS-1 cells,
including global folding, disulfide bonding, subcellular localization, and tetrameric subunit assembly. These findings are consistent with previous mutagenesis studies showing that gross

FIG. 8. Effects of neutralizing conserved CHR residues. Helical
models of WT and mutant P/rds sequences illustrate hydrophobic faces
(shaded) and residues targeted in this study (boxed). The consequences
of the substitutions are indicated below each variant. Data are summarized as follows: ⫹⫹, enhanced; ⫹, WT P/rds; ⫺, inhibited; ND, not
determined.

protein structural properties, including folding, disulfide formation, subunit assembly, and endoplasmic reticulum export,
are dependent upon determinants within the EC2 domain, but
not the C terminus (22, 32, 43). Likewise, none of the CHR
mutations examined here measurably affected OS targeting
and localization in transgenic X. laevis photoreceptors. Given
that the two charged residues targeted in this study reside
within a previously identified OS localization signal, it is noteworthy that substitutions at the conserved Glu321 and Lys324
residues do not disrupt targeting. The high degree of conservation at these positions likely reflects their participation in
other molecular activities. In addition, the demonstration that
these charged residues are not required for OS localization
indicates that their absence in the C terminus of the P/rds
homolog rom-1 is not responsible for the lack of targeting
activity observed for that molecule (20). Given current knowledge, we consider that multiple roles for the C terminus are
likely and have proposed P/rds multifunctionality previously
(22). A more detailed investigation will be required to determine whether expression of these mutant variants in transgenic X. laevis photoreceptors affects OS ultrastructure and
GFP localization at the ultrastructural level.
In sharp contrast, all of the mutations reported here had
dramatic consequences on P/rds interaction with model membranes. Mechanisms of fusion peptide action are likely manifold and are currently being debated; however, it is generally
agreed that they function as oligomers and must bind and
destabilize membrane surfaces (26). All three mutations described here strongly affected both membrane fusion, measured by lipid mixing, and membrane destabilization, measured
potentiometrically. Neutralization of either Glu321 or Lys324
largely prevented model membrane fusion (Fig. 8). Since individual mutations at these positions also severely inhibited destabilization, it is likely that these mutations impede membrane adhesion and/or bilayer penetration. Additional studies
are required to evaluate potential contributions from each of
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these mechanisms. Interestingly, simultaneous neutralization
of charged residues in the double mutant also inhibited fusion,
but significantly enhanced destabilization. Since fusogenic activity requires peptide oligomerization, but destabilization does
not, these results suggest an inhibition of double mutant selfassociation at the membrane surface (66, 67). Although limited
evidence suggests that the P/rds fusion peptide may oligomerize in aqueous solution, its self-association state while bound to
membranes is not known (24). The increased destabilization
produced by concurrent loss of Glu321 and Lys324 suggests that
the double mutant peptide may penetrate more deeply into the
bilayer, akin to effects seen for neutralizing mutations within
the hemagglutinin fusion peptide (29, 62, 65). It is not apparent
why the single charge neutralization mutants do not also increase destabilization, and reconciling these differences will
require atomic level structural detail of the peptides in their
membrane-bound states. Overall, these findings demonstrate
an uncoupling of fusogenic activity from other protein properties and suggest the utility of using non-fusogenic P/rds to
genetically complement rds mice to test the hypothesis that
fusogenic activity is important for photoreceptor OS renewal.
More than a dozen mutations in the P/rds C terminus have
been associated with instances of human retinal disease. Defects include missense, nonsense, splice, insertion, and deletion
mutations, and clinical phenotypes include autosomal dominant retinitis pigmentosa, cone dystrophy, pattern dystrophy,
adult vitelliform macular dystrophy, and butterfly-shaped
macular dystrophy (68 –71). A mouse model for autosomal dominant retinitis pigmentosa that possesses a ⌬307 frameshift
mutation leads to complete loss of the CHR and compromises
photoreceptor viability (59). Since a truncation of the CHR has
previously been shown to inhibit fusogenic activity (25), it is
possible that fusogenic loss of function could contribute to the
⌬307 frameshift phenotype. This mutation generates a dominant-negative phenotype, suggesting that the resulting gene
product can inhibit WT protein function. Co-assembly (in heterozygotes) of non-fusogenic P/rds with WT P/rds is likewise
predicted to inhibit WT protein function since C-terminal domain mutations do not impair subunit assembly (22). Incorporation of even a single mutant polypeptide into an otherwise
WT tetramer could affect activity since fusion proteins are
known to function as oligomers (26). This possibility remains
likely even if the ⌬307 frameshift inactivates the OS localization signal since mutant polypeptide assembly into WT proteincontaining tetramers is predicted to effectively mask localization signal defects. Furthermore, quality control mechanisms
that prevent P/rds exit from the biosynthetic pathway fail to
distinguish mutant polypeptides that are assembled into normal tetramers (58). Thus, a loss of fusogenic activity is predicted to result in a dominant-negative phenotype for individuals inheriting the ⌬307 frameshift mutation. In the absence of
additional information, we do not exclude the possibility that
the ⌬307 frameshift mutation may cause impaired targeting to
the photoreceptor OS, disruption of OS protein-protein interactions, and/or deleterious new interactions generated by the
novel protein sequence resulting from the frameshift.
We have addressed the importance of conserved charged
residues located within the P/rds CHR and found they are
critical for interactions with model membranes, but not protein
biosynthesis or OS localization. The findings lead us to conclude that determinants for OS localization and fusogenic activity are overlapping yet distinct. This conclusion reinforces
our notion that a multiplicity of molecular pathologies may
contribute to the phenotypic heterogeneity characteristic of
P/rds-associated diseases and suggests that a dominant-negative phenotype associated with a ⌬307 frameshift mutation

may result from an uncoupling of fusogenic activity. Determination of whether OS renewal can be restored in rds mice by
transgenic complementation with non-fusogenic yet otherwise
normal P/rds will be facilitated by the findings described here
and will provide additional insights into P/rds action within the
vertebrate photoreceptor.
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